FindTrial
Sign In

Multigene combination predicts prostate cancer recurrence

Multigene combination predicts prostate cancer recurrence

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052772
Enrollment
Unknown
Registered
2021-11-05
Start date
2021-11-05
Completion date
Unknown
Last updated
2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

case series:None

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Prostate cancer patients treated with radical prostatectomy between 2013 and 2021. 2. Pathologically diagnosed with prostate cancer.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete follow-up information or no follow-up information after surgery. 2. Patients with short follow-up time. 3. Patients undergoing neoadjuvant endocrine therapy. 4. Patients with postoperative adjuvant endocrine therapy and unable to judge the biochemical recurrence.

Design outcomes

Primary

MeasureTime frame
RNA;Biochemical recurrence of prostate cancer;—

Countries

China

Contacts

Public ContactChen Rui

Shanghai Changhai Hospital

drchenrui@foxmail.com+86 13764301103

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026